Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521154 · ClinicalTrials.gov registry record · Phase 3
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A Phase 3 study of Non-Small Cell Lung Cancer (Stage III), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
- 20
- Study locations
NCT03521154: Active Phase 3 study of Non-Small Cell Lung Cancer (Stage III), sponsored by AstraZeneca.
NCT03521154 is a Phase 3 study of Non-Small Cell Lung Cancer (Stage III) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 216 participants, above the 61-participant average among 8 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (254% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03521154, a Phase 3 study of Non-Small Cell Lung Cancer (Stage III), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Primary Outcome
Time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1
Conditions Studied
Interventions
- DRUG Osimertinib 80mg/40mg
- DRUG Placebo Osimertinib 80mg/40mg
Study Locations (20)
Other
- Research Site - Ciudad Autónoma de Bs. As.
- Research Site - Ciudad Autónoma de Bs. As.
- Research Site - Mar del Plata
- Research Site - Rosario
- Research Site - San Salvador de Jujuy
- Research Site - Barretos
- Research Site - Curitiba
- Research Site - Florianópolis
- Research Site - Fortaleza
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Ribeirão Preto
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Beijing
California
- Research Site - Duarte
Georgia
- Research Site - Atlanta
New Jersey
- Research Site - Florham Park
Utah
- Research Site - Salt Lake City
Wisconsin
- Research Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2027-04-13 |
| Phase | Phase 3 |
What the registry record for NCT03521154 still lists
NCT03521154 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 8 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (254% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer (Stage III) appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib 80mg/40mg is the first listed.
NCT03521154 names 20 study sites across 6 states, led by Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03521154 about?
NCT03521154 is a clinical study titled "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)". A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
What is the current status of trial NCT03521154?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2018-07-19. Estimated completion is 2027-04-13.
What conditions does trial NCT03521154 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer (Stage III).
What interventions are being tested in trial NCT03521154?
The interventions under investigation include: Osimertinib 80mg/40mg (DRUG), Placebo Osimertinib 80mg/40mg (DRUG).
Who is sponsoring clinical trial NCT03521154?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03521154 being conducted?
This trial has 20 study locations across California, Georgia, New Jersey, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer (Stage III)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03521154's enrollment target sits among peer trials
216 1st of 8 higher than 8 of 8 other Non-Small Cell Lung Cancer (Stage III) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer (Stage III) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HEARTS Trial for Thoracic Cancers
RECRUITING · Phase 2
-
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RECRUITING · Phase 2
-
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
RECRUITING · Phase 2
-
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
RECRUITING · Phase 2
-
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI